State legislation that would restrict dispensing biosimilars would raise drug costs for patients, employers and public health programs, PCMA says. "[C]ampaigning to restrict the use of biosimilars enriches brand manufacturers at the expense of the employers, public health programs, and patients who need access to lower cost medicines," PCMA President and CEO Mark Merritt said.

Related Summaries